Navigation Links
VIVUS to Present at the Credit Suisse 2011 Healthcare Conference
Date:11/3/2011

MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Credit Suisse 2011 Healthcare Conference.

The VIVUS presentation will take place at the Arizona Biltmore Hotel in Phoenix, AZ on Thursday, November 10, 2011 at 9:30 a.m. MST.  A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial Qnexa NDA on October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction, with an FDA action date of April 29, 2012. For more information about the company, please visit www.vivus.com.

 CONTACT: 

  

 

 VIVUS, Inc. Investor Relations:The Trout Group 

 

 Timothy E. Morris 

Brian KorbChief Financial Officer 

bkorb@troutgroup.com 

 

 650-934-52 

646-378-2923   
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. VIVUS Resubmits Qnexa NDA to the FDA
2. VIVUS Provides Regulatory Update on QNEXA
3. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
4. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
5. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
6. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
7. VIVUS to Present at Three Upcoming Investor Conferences in March
8. VIVUS Provides Regulatory Update on QNEXA NDA
9. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
10. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
11. VIVUS to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Research and Markets has announced the addition ... report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and ... global Fibromyalgia market. The research answers the following questions: ... Fibromyalgia and their clinical attributes? How are they positioned in the ...
(Date:2/23/2017)... Feb. 23, 2017 Regulus Therapeutics Inc ... and development of innovative medicines targeting microRNAs, today announced ... financial results on Thursday, March 2, 2017 after the ... call and webcast on March 2, 2017 at 5:00 ... year 2016 financial results and provide a general business ...
(Date:2/23/2017)... India , February 23, 2017 ... Imaging Market by Product (X-ray Imaging Digital, Analog), MRI ... Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging ... the report studies the global market over the forecast ... to reach ~USD 36.43 Billion by 2021, at a ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... ... The California State University Institute for Palliative Care is pleased ... palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing Academic Palliative ... Sept. 28 and 29, 2017, on the campus of California State University San Marcos. ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management Association will ... at the annual Building Better Radiology Marketing Programs conference, held this year ... Worth, Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, ... with The Jensie Gran Fondo of Marin. For the second year in a ... broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... media outlet with a clinician-based audience, will be participating in Rare Disease Day ... in Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a national ... marketing, social media management, corporate communications, SEO and cause marketing, is opening an ... nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. ...
Breaking Medicine News(10 mins):